Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 28Lung Neoplasms 27Neoplasm Metastasis 26Carcinoma, Non-Small-Cell Lung 20Multiple Myeloma 18Breast Neoplasms 17Urinary Bladder Neoplasms 16Lymphoma 15Glioma 15Colorectal Neoplasms 14Pancreatic Neoplasms 13Carcinoma, Renal Cell 13Squamous Cell Carcinoma of Head and Neck 12Ovarian Neoplasms 12Melanoma 12Lymphoma, Large B-Cell, Diffuse 12Triple Negative Breast Neoplasms 11Oropharyngeal Neoplasms 9Mouth Neoplasms 9Glioblastoma 9Fallopian Tube Neoplasms 9Carcinoma 9Sarcoma 8Lymphoma, Non-Hodgkin 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Medulloblastoma 7Lymphoma, Follicular 7Laryngeal Neoplasms 7Carcinoma, Hepatocellular 7

Interventions

tislelizumab 3pembrolizumab 3Injections 2toripalimab 1Nivolumab 1Magnetic Resonance Spectroscopy 1Fulvestrant 1Drug Therapy 1CD3 Complex 1Bevacizumab 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumor × Magnetic Resonance Spectroscopy × 30 days × Clear all
NCT05599048 2026-05-27

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

University of California, San Francisco

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡